Hepatitis C virus (HCV) remains a global health challenge, despite direct-acting antivirals achieving cure rates over 95%. In the United States, the opioid crisis and disruptions from COVID-19 have exacerbated HCV infections. The updated AASLD-IDSA guidelines emphasize universal screening, minimal monitoring, and simplified treatment regimens. High-risk groups, including people who inject drugs and incarcerated individuals, require regular testing, while streamlined treatment options address both treatment-naïve and experienced patients.

Globally, tailored strategies are essential to improve access and affordability. In the United States, integrating harm reduction efforts, like linking opioid-impacted populations to care, is critical. Successful models, such as Louisiana’s Payer License Agreement and Egypt’s national HCV program, highlight innovative approaches to treatment access. Simplified algorithms, cost-effective regimens, and partnerships among policymakers, healthcare providers, and pharmaceutical companies are key to eliminating HCV. Collaborative efforts to ensure prevention, affordable treatment, and care linkage are vital to achieving global HCV eradication.

Reference: Pan CQ, Park JS. Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment. Transl Gastroenterol Hepatol. 2024;9:30. doi: 10.21037/tgh-23-104.